Global Drug-Device Combination Products Market Outlook and Growth Opportunities 2025

Summary

According to APO Research, the global Drug-Device Combination Products market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Drug-Device Combination Products is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.

The Asia-Pacific market for Drug-Device Combination Products is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Drug-Device Combination Products market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.

The Europe market for Drug-Device Combination Products is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Drug-Device Combination Products market include GSK, Abbott, MicroPort, Medtronic, Eli Lilly, Lepu Medical, Boston Scientific, B. Braun and Viatris, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.

This report presents an overview of global market for Drug-Device Combination Products, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Drug-Device Combination Products, also provides the value of main regions and countries. Of the upcoming market potential for Drug-Device Combination Products, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Drug-Device Combination Products revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Drug-Device Combination Products market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Drug-Device Combination Products company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.

Drug-Device Combination Products Segment by Company

GSK
Abbott
MicroPort
Medtronic
Eli Lilly
Lepu Medical
Boston Scientific
B. Braun
Viatris
Terumo
Teleflex
Smith & Nephew
Sanofi
Novo Nordisk
Molnlycke
Hisamitsu
Boehringer Ingelheim
BD
AstraZeneca
Antares Pharma
3M
Drug-Device Combination Products Segment by Type

Transdermal Delivery System
Nebulizer and Inhaler
Drug-Coated Device
Prefilled Drug Delivery Systems
Others
Drug-Device Combination Products Segment by Application

Hospital andClinic
Retail Pharmacies
Other
Drug-Device Combination Products Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global Drug-Device Combination Products status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Drug-Device Combination Products key companies, revenue, market share, and recent developments.
3. To split the Drug-Device Combination Products breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Drug-Device Combination Products market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Drug-Device Combination Products significant trends, drivers, influence factors in global and regions.
6. To analyze Drug-Device Combination Products competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drug-Device Combination Products market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Drug-Device Combination Products and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drug-Device Combination Products.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Drug-Device Combination Products industry.
Chapter 3: Detailed analysis of Drug-Device Combination Products company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Drug-Device Combination Products in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Drug-Device Combination Products in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview
1.1 Product Definition
1.2 Global Drug-Device Combination Products Market Size, 2020 VS 2024 VS 2031
1.3 Global Drug-Device Combination Products Market Size (2020-2031)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Drug-Device Combination Products Market Dynamics
2.1 Drug-Device Combination Products Industry Trends
2.2 Drug-Device Combination Products Industry Drivers
2.3 Drug-Device Combination Products Industry Opportunities and Challenges
2.4 Drug-Device Combination Products Industry Restraints
3 Drug-Device Combination Products Market by Company
3.1 Global Drug-Device Combination Products Company Revenue Ranking in 2024
3.2 Global Drug-Device Combination Products Revenue by Company (2020-2025)
3.3 Global Drug-Device Combination Products Company Ranking (2023-2025)
3.4 Global Drug-Device Combination Products Company Manufacturing Base and Headquarters
3.5 Global Drug-Device Combination Products Company Product Type and Application
3.6 Global Drug-Device Combination Products Company Establishment Date
3.7 Market Competitive Analysis
3.7.1 Global Drug-Device Combination Products Market Concentration Ratio (CR5 and HHI)
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.7.3 2024 Drug-Device Combination Products Tier 1, Tier 2, and Tier 3 Companies
3.8 Mergers and Acquisitions Expansion
4 Drug-Device Combination Products Market by Type
4.1 Drug-Device Combination Products Type Introduction
4.1.1 Transdermal Delivery System
4.1.2 Nebulizer and Inhaler
4.1.3 Drug-Coated Device
4.1.4 Prefilled Drug Delivery Systems
4.1.5 Others
4.2 Global Drug-Device Combination Products Sales Value by Type
4.2.1 Global Drug-Device Combination Products Sales Value by Type (2020 VS 2024 VS 2031)
4.2.2 Global Drug-Device Combination Products Sales Value by Type (2020-2031)
4.2.3 Global Drug-Device Combination Products Sales Value Share by Type (2020-2031)
5 Drug-Device Combination Products Market by Application
5.1 Drug-Device Combination Products Application Introduction
5.1.1 Hospital andClinic
5.1.2 Retail Pharmacies
5.1.3 Other
5.2 Global Drug-Device Combination Products Sales Value by Application
5.2.1 Global Drug-Device Combination Products Sales Value by Application (2020 VS 2024 VS 2031)
5.2.2 Global Drug-Device Combination Products Sales Value by Application (2020-2031)
5.2.3 Global Drug-Device Combination Products Sales Value Share by Application (2020-2031)
6 Drug-Device Combination Products Regional Value Analysis
6.1 Global Drug-Device Combination Products Sales Value by Region: 2020 VS 2024 VS 2031
6.2 Global Drug-Device Combination Products Sales Value by Region (2020-2031)
6.2.1 Global Drug-Device Combination Products Sales Value by Region: 2020-2025
6.2.2 Global Drug-Device Combination Products Sales Value by Region (2026-2031)
6.3 North America
6.3.1 North America Drug-Device Combination Products Sales Value (2020-2031)
6.3.2 North America Drug-Device Combination Products Sales Value Share by Country, 2024 VS 2031
6.4 Europe
6.4.1 Europe Drug-Device Combination Products Sales Value (2020-2031)
6.4.2 Europe Drug-Device Combination Products Sales Value Share by Country, 2024 VS 2031
6.5 Asia-Pacific
6.5.1 Asia-Pacific Drug-Device Combination Products Sales Value (2020-2031)
6.5.2 Asia-Pacific Drug-Device Combination Products Sales Value Share by Country, 2024 VS 2031
6.6 South America
6.6.1 South America Drug-Device Combination Products Sales Value (2020-2031)
6.6.2 South America Drug-Device Combination Products Sales Value Share by Country, 2024 VS 2031
6.7 Middle East & Africa
6.7.1 Middle East & Africa Drug-Device Combination Products Sales Value (2020-2031)
6.7.2 Middle East & Africa Drug-Device Combination Products Sales Value Share by Country, 2024 VS 2031
7 Drug-Device Combination Products Country-level Value Analysis
7.1 Global Drug-Device Combination Products Sales Value by Country: 2020 VS 2024 VS 2031
7.2 Global Drug-Device Combination Products Sales Value by Country (2020-2031)
7.2.1 Global Drug-Device Combination Products Sales Value by Country (2020-2025)
7.2.2 Global Drug-Device Combination Products Sales Value by Country (2026-2031)
7.3 USA
7.3.1 USA Drug-Device Combination Products Sales Value Growth Rate (2020-2031)
7.3.2 USA Drug-Device Combination Products Sales Value Share by Type, 2024 VS 2031
7.3.3 USA Drug-Device Combination Products Sales Value Share by Application, 2024 VS 2031
7.4 Canada
7.4.1 Canada Drug-Device Combination Products Sales Value Growth Rate (2020-2031)
7.4.2 Canada Drug-Device Combination Products Sales Value Share by Type, 2024 VS 2031
7.4.3 Canada Drug-Device Combination Products Sales Value Share by Application, 2024 VS 2031
7.5 Mexico
7.5.1 Mexico Drug-Device Combination Products Sales Value Growth Rate (2020-2031)
7.5.2 Mexico Drug-Device Combination Products Sales Value Share by Type, 2024 VS 2031
7.5.3 Mexico Drug-Device Combination Products Sales Value Share by Application, 2024 VS 2031
7.6 Germany
7.6.1 Germany Drug-Device Combination Products Sales Value Growth Rate (2020-2031)
7.6.2 Germany Drug-Device Combination Products Sales Value Share by Type, 2024 VS 2031
7.6.3 Germany Drug-Device Combination Products Sales Value Share by Application, 2024 VS 2031
7.7 France
7.7.1 France Drug-Device Combination Products Sales Value Growth Rate (2020-2031)
7.7.2 France Drug-Device Combination Products Sales Value Share by Type, 2024 VS 2031
7.7.3 France Drug-Device Combination Products Sales Value Share by Application, 2024 VS 2031
7.8 U.K.
7.8.1 U.K. Drug-Device Combination Products Sales Value Growth Rate (2020-2031)
7.8.2 U.K. Drug-Device Combination Products Sales Value Share by Type, 2024 VS 2031
7.8.3 U.K. Drug-Device Combination Products Sales Value Share by Application, 2024 VS 2031
7.9 Italy
7.9.1 Italy Drug-Device Combination Products Sales Value Growth Rate (2020-2031)
7.9.2 Italy Drug-Device Combination Products Sales Value Share by Type, 2024 VS 2031
7.9.3 Italy Drug-Device Combination Products Sales Value Share by Application, 2024 VS 2031
7.10 Spain
7.10.1 Spain Drug-Device Combination Products Sales Value Growth Rate (2020-2031)
7.10.2 Spain Drug-Device Combination Products Sales Value Share by Type, 2024 VS 2031
7.10.3 Spain Drug-Device Combination Products Sales Value Share by Application, 2024 VS 2031
7.11 Russia
7.11.1 Russia Drug-Device Combination Products Sales Value Growth Rate (2020-2031)
7.11.2 Russia Drug-Device Combination Products Sales Value Share by Type, 2024 VS 2031
7.11.3 Russia Drug-Device Combination Products Sales Value Share by Application, 2024 VS 2031
7.12 Netherlands
7.12.1 Netherlands Drug-Device Combination Products Sales Value Growth Rate (2020-2031)
7.12.2 Netherlands Drug-Device Combination Products Sales Value Share by Type, 2024 VS 2031
7.12.3 Netherlands Drug-Device Combination Products Sales Value Share by Application, 2024 VS 2031
7.13 Nordic Countries
7.13.1 Nordic Countries Drug-Device Combination Products Sales Value Growth Rate (2020-2031)
7.13.2 Nordic Countries Drug-Device Combination Products Sales Value Share by Type, 2024 VS 2031
7.13.3 Nordic Countries Drug-Device Combination Products Sales Value Share by Application, 2024 VS 2031
7.14 China
7.14.1 China Drug-Device Combination Products Sales Value Growth Rate (2020-2031)
7.14.2 China Drug-Device Combination Products Sales Value Share by Type, 2024 VS 2031
7.14.3 China Drug-Device Combination Products Sales Value Share by Application, 2024 VS 2031
7.15 Japan
7.15.1 Japan Drug-Device Combination Products Sales Value Growth Rate (2020-2031)
7.15.2 Japan Drug-Device Combination Products Sales Value Share by Type, 2024 VS 2031
7.15.3 Japan Drug-Device Combination Products Sales Value Share by Application, 2024 VS 2031
7.16 South Korea
7.16.1 South Korea Drug-Device Combination Products Sales Value Growth Rate (2020-2031)
7.16.2 South Korea Drug-Device Combination Products Sales Value Share by Type, 2024 VS 2031
7.16.3 South Korea Drug-Device Combination Products Sales Value Share by Application, 2024 VS 2031
7.17 India
7.17.1 India Drug-Device Combination Products Sales Value Growth Rate (2020-2031)
7.17.2 India Drug-Device Combination Products Sales Value Share by Type, 2024 VS 2031
7.17.3 India Drug-Device Combination Products Sales Value Share by Application, 2024 VS 2031
7.18 Australia
7.18.1 Australia Drug-Device Combination Products Sales Value Growth Rate (2020-2031)
7.18.2 Australia Drug-Device Combination Products Sales Value Share by Type, 2024 VS 2031
7.18.3 Australia Drug-Device Combination Products Sales Value Share by Application, 2024 VS 2031
7.19 Southeast Asia
7.19.1 Southeast Asia Drug-Device Combination Products Sales Value Growth Rate (2020-2031)
7.19.2 Southeast Asia Drug-Device Combination Products Sales Value Share by Type, 2024 VS 2031
7.19.3 Southeast Asia Drug-Device Combination Products Sales Value Share by Application, 2024 VS 2031
7.20 Brazil
7.20.1 Brazil Drug-Device Combination Products Sales Value Growth Rate (2020-2031)
7.20.2 Brazil Drug-Device Combination Products Sales Value Share by Type, 2024 VS 2031
7.20.3 Brazil Drug-Device Combination Products Sales Value Share by Application, 2024 VS 2031
7.21 Argentina
7.21.1 Argentina Drug-Device Combination Products Sales Value Growth Rate (2020-2031)
7.21.2 Argentina Drug-Device Combination Products Sales Value Share by Type, 2024 VS 2031
7.21.3 Argentina Drug-Device Combination Products Sales Value Share by Application, 2024 VS 2031
7.22 Chile
7.22.1 Chile Drug-Device Combination Products Sales Value Growth Rate (2020-2031)
7.22.2 Chile Drug-Device Combination Products Sales Value Share by Type, 2024 VS 2031
7.22.3 Chile Drug-Device Combination Products Sales Value Share by Application, 2024 VS 2031
7.23 Colombia
7.23.1 Colombia Drug-Device Combination Products Sales Value Growth Rate (2020-2031)
7.23.2 Colombia Drug-Device Combination Products Sales Value Share by Type, 2024 VS 2031
7.23.3 Colombia Drug-Device Combination Products Sales Value Share by Application, 2024 VS 2031
7.24 Peru
7.24.1 Peru Drug-Device Combination Products Sales Value Growth Rate (2020-2031)
7.24.2 Peru Drug-Device Combination Products Sales Value Share by Type, 2024 VS 2031
7.24.3 Peru Drug-Device Combination Products Sales Value Share by Application, 2024 VS 2031
7.25 Saudi Arabia
7.25.1 Saudi Arabia Drug-Device Combination Products Sales Value Growth Rate (2020-2031)
7.25.2 Saudi Arabia Drug-Device Combination Products Sales Value Share by Type, 2024 VS 2031
7.25.3 Saudi Arabia Drug-Device Combination Products Sales Value Share by Application, 2024 VS 2031
7.26 Israel
7.26.1 Israel Drug-Device Combination Products Sales Value Growth Rate (2020-2031)
7.26.2 Israel Drug-Device Combination Products Sales Value Share by Type, 2024 VS 2031
7.26.3 Israel Drug-Device Combination Products Sales Value Share by Application, 2024 VS 2031
7.27 UAE
7.27.1 UAE Drug-Device Combination Products Sales Value Growth Rate (2020-2031)
7.27.2 UAE Drug-Device Combination Products Sales Value Share by Type, 2024 VS 2031
7.27.3 UAE Drug-Device Combination Products Sales Value Share by Application, 2024 VS 2031
7.28 Turkey
7.28.1 Turkey Drug-Device Combination Products Sales Value Growth Rate (2020-2031)
7.28.2 Turkey Drug-Device Combination Products Sales Value Share by Type, 2024 VS 2031
7.28.3 Turkey Drug-Device Combination Products Sales Value Share by Application, 2024 VS 2031
7.29 Iran
7.29.1 Iran Drug-Device Combination Products Sales Value Growth Rate (2020-2031)
7.29.2 Iran Drug-Device Combination Products Sales Value Share by Type, 2024 VS 2031
7.29.3 Iran Drug-Device Combination Products Sales Value Share by Application, 2024 VS 2031
7.30 Egypt
7.30.1 Egypt Drug-Device Combination Products Sales Value Growth Rate (2020-2031)
7.30.2 Egypt Drug-Device Combination Products Sales Value Share by Type, 2024 VS 2031
7.30.3 Egypt Drug-Device Combination Products Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 GSK
8.1.1 GSK Comapny Information
8.1.2 GSK Business Overview
8.1.3 GSK Drug-Device Combination Products Revenue and Gross Margin (2020-2025)
8.1.4 GSK Drug-Device Combination Products Product Portfolio
8.1.5 GSK Recent Developments
8.2 Abbott
8.2.1 Abbott Comapny Information
8.2.2 Abbott Business Overview
8.2.3 Abbott Drug-Device Combination Products Revenue and Gross Margin (2020-2025)
8.2.4 Abbott Drug-Device Combination Products Product Portfolio
8.2.5 Abbott Recent Developments
8.3 MicroPort
8.3.1 MicroPort Comapny Information
8.3.2 MicroPort Business Overview
8.3.3 MicroPort Drug-Device Combination Products Revenue and Gross Margin (2020-2025)
8.3.4 MicroPort Drug-Device Combination Products Product Portfolio
8.3.5 MicroPort Recent Developments
8.4 Medtronic
8.4.1 Medtronic Comapny Information
8.4.2 Medtronic Business Overview
8.4.3 Medtronic Drug-Device Combination Products Revenue and Gross Margin (2020-2025)
8.4.4 Medtronic Drug-Device Combination Products Product Portfolio
8.4.5 Medtronic Recent Developments
8.5 Eli Lilly
8.5.1 Eli Lilly Comapny Information
8.5.2 Eli Lilly Business Overview
8.5.3 Eli Lilly Drug-Device Combination Products Revenue and Gross Margin (2020-2025)
8.5.4 Eli Lilly Drug-Device Combination Products Product Portfolio
8.5.5 Eli Lilly Recent Developments
8.6 Lepu Medical
8.6.1 Lepu Medical Comapny Information
8.6.2 Lepu Medical Business Overview
8.6.3 Lepu Medical Drug-Device Combination Products Revenue and Gross Margin (2020-2025)
8.6.4 Lepu Medical Drug-Device Combination Products Product Portfolio
8.6.5 Lepu Medical Recent Developments
8.7 Boston Scientific
8.7.1 Boston Scientific Comapny Information
8.7.2 Boston Scientific Business Overview
8.7.3 Boston Scientific Drug-Device Combination Products Revenue and Gross Margin (2020-2025)
8.7.4 Boston Scientific Drug-Device Combination Products Product Portfolio
8.7.5 Boston Scientific Recent Developments
8.8 B. Braun
8.8.1 B. Braun Comapny Information
8.8.2 B. Braun Business Overview
8.8.3 B. Braun Drug-Device Combination Products Revenue and Gross Margin (2020-2025)
8.8.4 B. Braun Drug-Device Combination Products Product Portfolio
8.8.5 B. Braun Recent Developments
8.9 Viatris
8.9.1 Viatris Comapny Information
8.9.2 Viatris Business Overview
8.9.3 Viatris Drug-Device Combination Products Revenue and Gross Margin (2020-2025)
8.9.4 Viatris Drug-Device Combination Products Product Portfolio
8.9.5 Viatris Recent Developments
8.10 Terumo
8.10.1 Terumo Comapny Information
8.10.2 Terumo Business Overview
8.10.3 Terumo Drug-Device Combination Products Revenue and Gross Margin (2020-2025)
8.10.4 Terumo Drug-Device Combination Products Product Portfolio
8.10.5 Terumo Recent Developments
8.11 Teleflex
8.11.1 Teleflex Comapny Information
8.11.2 Teleflex Business Overview
8.11.3 Teleflex Drug-Device Combination Products Revenue and Gross Margin (2020-2025)
8.11.4 Teleflex Drug-Device Combination Products Product Portfolio
8.11.5 Teleflex Recent Developments
8.12 Smith & Nephew
8.12.1 Smith & Nephew Comapny Information
8.12.2 Smith & Nephew Business Overview
8.12.3 Smith & Nephew Drug-Device Combination Products Revenue and Gross Margin (2020-2025)
8.12.4 Smith & Nephew Drug-Device Combination Products Product Portfolio
8.12.5 Smith & Nephew Recent Developments
8.13 Sanofi
8.13.1 Sanofi Comapny Information
8.13.2 Sanofi Business Overview
8.13.3 Sanofi Drug-Device Combination Products Revenue and Gross Margin (2020-2025)
8.13.4 Sanofi Drug-Device Combination Products Product Portfolio
8.13.5 Sanofi Recent Developments
8.14 Novo Nordisk
8.14.1 Novo Nordisk Comapny Information
8.14.2 Novo Nordisk Business Overview
8.14.3 Novo Nordisk Drug-Device Combination Products Revenue and Gross Margin (2020-2025)
8.14.4 Novo Nordisk Drug-Device Combination Products Product Portfolio
8.14.5 Novo Nordisk Recent Developments
8.15 Molnlycke
8.15.1 Molnlycke Comapny Information
8.15.2 Molnlycke Business Overview
8.15.3 Molnlycke Drug-Device Combination Products Revenue and Gross Margin (2020-2025)
8.15.4 Molnlycke Drug-Device Combination Products Product Portfolio
8.15.5 Molnlycke Recent Developments
8.16 Hisamitsu
8.16.1 Hisamitsu Comapny Information
8.16.2 Hisamitsu Business Overview
8.16.3 Hisamitsu Drug-Device Combination Products Revenue and Gross Margin (2020-2025)
8.16.4 Hisamitsu Drug-Device Combination Products Product Portfolio
8.16.5 Hisamitsu Recent Developments
8.17 Boehringer Ingelheim
8.17.1 Boehringer Ingelheim Comapny Information
8.17.2 Boehringer Ingelheim Business Overview
8.17.3 Boehringer Ingelheim Drug-Device Combination Products Revenue and Gross Margin (2020-2025)
8.17.4 Boehringer Ingelheim Drug-Device Combination Products Product Portfolio
8.17.5 Boehringer Ingelheim Recent Developments
8.18 BD
8.18.1 BD Comapny Information
8.18.2 BD Business Overview
8.18.3 BD Drug-Device Combination Products Revenue and Gross Margin (2020-2025)
8.18.4 BD Drug-Device Combination Products Product Portfolio
8.18.5 BD Recent Developments
8.19 AstraZeneca
8.19.1 AstraZeneca Comapny Information
8.19.2 AstraZeneca Business Overview
8.19.3 AstraZeneca Drug-Device Combination Products Revenue and Gross Margin (2020-2025)
8.19.4 AstraZeneca Drug-Device Combination Products Product Portfolio
8.19.5 AstraZeneca Recent Developments
8.20 Antares Pharma
8.20.1 Antares Pharma Comapny Information
8.20.2 Antares Pharma Business Overview
8.20.3 Antares Pharma Drug-Device Combination Products Revenue and Gross Margin (2020-2025)
8.20.4 Antares Pharma Drug-Device Combination Products Product Portfolio
8.20.5 Antares Pharma Recent Developments
8.21 3M
8.21.1 3M Comapny Information
8.21.2 3M Business Overview
8.21.3 3M Drug-Device Combination Products Revenue and Gross Margin (2020-2025)
8.21.4 3M Drug-Device Combination Products Product Portfolio
8.21.5 3M Recent Developments
9 Concluding Insights
10 Appendix
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings